KEYNOTE-024: Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

URI: https://gptkb.org/entity/KEYNOTE-024:_Pembrolizumab_versus_Chemotherapy_for_PD-L1–Positive_Non–Small-Cell_Lung_Cancer
GPTKB entity
Statements (23)
Predicate Object
gptkbp:instanceOf gptkb:clinical_trial
gptkbp:alsoKnownAs gptkb:KEYNOTE-024
gptkbp:author gptkb:Martin_Reck
gptkbp:clinicalTrials.govID gptkb:NCT02142738
gptkbp:comparator platinum-based chemotherapy
gptkbp:conditionStudied PD-L1–positive non–small-cell lung cancer
gptkbp:endPoint overall survival
progression-free survival
gptkbp:enrollment 305
https://www.w3.org/2000/01/rdf-schema#label KEYNOTE-024: Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
gptkbp:includes PD-L1 tumor proportion score ≥50%
gptkbp:period Phase III
gptkbp:publicationDate October 2016
gptkbp:publishedIn gptkb:New_England_Journal_of_Medicine
gptkbp:randomized yes
gptkbp:result pembrolizumab improved overall survival
pembrolizumab improved progression-free survival
lower rate of treatment-related adverse events with pembrolizumab
gptkbp:sponsor gptkb:Merck_&_Co.
gptkbp:startDate 2014
gptkbp:studiedDrug gptkb:pembrolizumab
gptkbp:bfsParent gptkb:KEYNOTE-024
gptkbp:bfsLayer 7